Clinically available since 1995* • More than 100,000 treatments performed • Reproducible clinical benefits
More than 200 scientific papers and peer reviewed articles available
Products are region specific and may not be approved in some countries/regions.
Please contact Spectral Medical Inc. at email@example.com to obtain appropriate product information for your country of residence. This product is currently undergoing clinical investigation in United States.
› PMX use improves hemodynamics
Multiple studies and meta-analyses consistently describe Toraymyxin‘s beneficial effect on patient hemodynamics (decrease of vasopressor requirements and an increase of MAP). Vincent et al. documented a favourable Toraymyxin effect on cardiac function in terms of increased Left Ventricular Stroke Work (LVSW) with no change in Pulmonary Capillary Wedge Pressure (PCWP).
› PMX use rapidly reverses organ dysfunction
Several studies reproducibly report that Toraymyxin treatment has a positive impact on organ dysfunction recovery. Among others, the EUPHAS trial describes a dramatic improvement in SOFA score within 24 hrs of treatment.
› PMX use reduces mortality
A recent meta-analysis by Kellum et al. of all randomized trials of blood purification strategies in sepsis including direct hemoperfusion with PMX showed an overall reduction in mortality from 50.1% to 35.7%, [Risk Ratio 0.69; 95% CI 0.56-0.84]. The authors highlighted that the result was mainly driven by the eight randomized trials for Toraymyxin which accounts for more than 370 of the 827 total patients, with a mortality reduction from 66.9% to 37.3% (calculated from the published data).
Detection and Removal of Endotoxin in Septic Shock:
The Theranostic Approach of the EUPHRATES Trial
The EUPHRATES trial (clinicaltrials.gov Identifier: NCT01046669) is currently being run in 50 centers in North America. It uses a theranostic approach for the management and treatment of endotoxin induced septic shock. Patients who present with clinical signs of septic shock are screened for endotoxin activity using the EAA™. Only patients with high levels of endotoxin activity are eligible to be randomized into this pivotal trial.
*(Year of PMX availability is as follows: 1995 in Japan, 2002 in Italy, 2007 in Spain, 2008 in India, and 2009 in Switzerland and Austria)
135 The West Mall, Unit 2 • Toronto, Ontario • M9C 1C2 Canada
Tel: 1.416.626.3233 • Toll Free: 1.888.426.4264 • Fax: 1.416.626.7383